PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Go back to PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program| PTC THERAPEUTICS (NASDAQ: PTCT) | Delayed: 65.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.26 | 52 Week High | $35.40 | |||
| Open | $65.26 | 52 Week Low | $4.03 | |||
| Day High | $65.26 | P/E | 6.94 | |||
| Day Low | $65.26 | EPS | $9.40 | |||
| Volume | 11,670 | |||||
